Cover Image
市場調查報告書

局部沾黏激酶:開發中產品分析

Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 367824
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
局部沾黏激酶:開發中產品分析 Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 72 Pages
簡介

本報告提供以局部沾黏激酶為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

局部沾黏激酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Asana BioSciences, LLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc
  • 武田藥品工業
  • Teva Pharmaceutical Industries Ltd.
  • Verastem, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0397TDB

Summary

Global Markets Direct's, 'Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Review, H2 2016', provides in depth analysis on Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Focal Adhesion Kinase (FAK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Focal Adhesion Kinase (FAK or EC 2.7.10.2)
  • The report reviews Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Focal Adhesion Kinase (FAK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Focal Adhesion Kinase (FAK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Focal Adhesion Kinase (FAK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) Overview
    • Therapeutics Development
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Stage of Development
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Therapy Area
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Indication
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Companies
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Products under Development by Universities/Institutes
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
    • Asana BioSciences, LLC
    • Boehringer Ingelheim GmbH
    • GlaxoSmithKline Plc
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Verastem, Inc.
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Drug Profiles
    • ASN-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-853520 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEP-37440 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cilengitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-707 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTX-0294886 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTX-0294945 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • defactinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2256098 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Focal Adhesion Kinase for Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit FAK for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Focal Adhesion Kinase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-4718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-6062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Dormant Projects
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Discontinued Products
  • Focal Adhesion Kinase (FAK or EC 2.7.10.2) - Featured News & Press Releases
    • Jul 05, 2016: Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer
    • May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology
    • May 04, 2016: Verastem Announces the Presentation of Clinical Data at iMig 2016
    • Mar 30, 2016: Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology
    • Mar 16, 2016: Verastem to Present Data Supporting FAK/PYK2 Inhibition at the 2016 American Academy of Cancer Research Annual Meeting
    • Mar 16, 2016: Verastem to present data supporting FAK inhibition at the 2016 American Academy of cancer research annual meeting
    • Jan 21, 2016: Verastem to Present Scientific Data Supporting FAK Inhibition in Combination with Immune Checkpoint Inhibitors at Immunotherapy World 2016
    • Jan 06, 2016: Washington University in St. Louis Initiates Clinical Study of Verastem's VS-6063 in Combination with Merck's Pembrolizumab and Gemcitabine in Pancreatic Cancer
    • Sep 28, 2015: Verastem Stops Enrollment Due to Futility in the Command Study of Vs-6063 for the Treatment of Malignant Pleural Mesothelioma
    • Sep 17, 2015: Verastem Announces Presentation On VS-6063 at ESMO/ECCO 2015
    • Sep 10, 2015: Verastem Presents Clinical and Preclinical Data at the 16th World Conference on Lung Cancer
    • Aug 26, 2015: Verastem to Present Data at the 16th World Conference on Lung Cancer
    • Dec 11, 2014: Verastem Presents Data at the 2014 San Antonio Breast Cancer Symposium
    • Dec 04, 2014: Verastem to Present Data on VS-6063 at the 2014 San Antonio Breast Cancer Symposium
    • Dec 04, 2014: Verastem to Present Data on VS-4718 at the 2014 San Antonio Breast Cancer Symposium
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Asana BioSciences, LLC, H2 2016
  • Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Pipeline by GlaxoSmithKline Plc, H2 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Pipeline by Verastem, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top